Compare TXMD & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXMD | FEMY |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 22.4M |
| IPO Year | 2012 | 2021 |
| Metric | TXMD | FEMY |
|---|---|---|
| Price | $1.85 | $1.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 18.2K | ★ 99.6K |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.68 | 44.71 |
| EPS | ★ 0.02 | N/A |
| Revenue | $1,761,000.00 | ★ $2,293,313.00 |
| Revenue This Year | $207.74 | N/A |
| Revenue Next Year | $2.15 | $328.45 |
| P/E Ratio | $92.50 | ★ N/A |
| Revenue Growth | 35.25 | ★ 40.77 |
| 52 Week Low | $1.11 | $0.29 |
| 52 Week High | $2.95 | $6.29 |
| Indicator | TXMD | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 28.20 | 28.45 |
| Support Level | N/A | $0.37 |
| Resistance Level | $2.16 | $3.21 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 16.13 | 7.34 |
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.